Bausch Health Companies (NYSE:BHC) Shares Down 5.2% - Should You Sell?

Bausch Health Companies Inc. (NYSE:BHC - Get Free Report)'s share price traded down 5.2% during mid-day trading on Monday . The company traded as low as $7.01 and last traded at $7.05. 488,195 shares changed hands during trading, a decline of 85% from the average session volume of 3,154,331 shares. The stock had previously closed at $7.43.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on BHC shares. Jefferies Financial Group restated a "hold" rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research report on Thursday. Royal Bank of Canada dropped their price target on Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a report on Thursday, January 30th. StockNews.com raised shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Friday, October 25th. Finally, Evercore ISI raised shares of Bausch Health Companies to a "hold" rating in a research note on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $7.42.

Bausch Health Companies Stock Down 10.8 %

The stock's fifty day moving average is $7.69 and its 200-day moving average is $7.45. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -13.64 and a beta of 0.68.

Institutional Trading of Bausch Health Companies

Hedge funds and other institutional investors have recently modified their holdings of the company. Tobam boosted its position in shares of Bausch Health Companies by 10.4% during the fourth quarter. Tobam now owns 15,034 shares of the company's stock worth $121,000 after buying an additional 1,422 shares during the period. DGS Capital Management LLC acquired a new position in Bausch Health Companies during the 4th quarter worth approximately $143,000. Principal Securities Inc. boosted its position in Bausch Health Companies by 39.7% during the 4th quarter. Principal Securities Inc. now owns 19,220 shares of the company's stock worth $155,000 after acquiring an additional 5,464 shares during the last quarter. Aigen Investment Management LP bought a new position in shares of Bausch Health Companies during the 4th quarter worth approximately $180,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Bausch Health Companies in the fourth quarter valued at approximately $180,000. Institutional investors and hedge funds own 78.65% of the company's stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.